Vimta Labs Reports Q1 FY27 Results; Total Income Reaches ₹1,129 Mn, Driven by Pharmaceutical Services
Hyderabad: Vimta Labs Limited, India's leading Contract Research and Testing Organisation (CRO), announced its unaudited financial results for the first quarter of Fiscal Year 2027 (Q1 FY27), which ended on June 30, 2026. The company reported a Total Income of ₹1,129 Mn for Q1 FY27.The comprehensive performance review reveals significant operational activity and expansion within the CRO landscape.
Financial Performance Snapshot (Q1 FY27)
Vimta Labs delivered strong results across key profitability metrics. For Q1 FY27, the company recorded an EBITDA of ₹411 Mn, resulting in an EBITDA margin of 36.4%. The Profit After Tax (PAT) was reported at ₹210 Mn, translating to a PAT margin of 18.6%. Basic Earnings Per Share (EPS) for Q1 FY27 stood at ₹4.7.The following table provides a detailed comparison of the financial metrics across recent quarters and years:
| Particulars (₹ Mn) | Q1 FY27 | Q4 FY26 | QoQ (%) | Q1 FY26 | YoY (%) |
|---|---|---|---|---|---|
| Total Income | 1,129 | 1,120 | 0.8% | 993 | 13.7% |
| EBITDA (including other income) | 411 | 421 | -2.4% | 354 | 16.0% |
| EBITDA Margin | 36.4% | 37.6% | 35.7% | ||
| PAT | 210 | 211 | -0.3% | 189 | 11.4% |
| PAT Margin | 18.6% | 18.9% | 19.0% | ||
| Basic EPS | 4.7 | 4.7 | -0.5% | 4.2 | 11.0% |
Management Commentary and Operational Highlights
Ms. Harita Vasireddi, Managing Director of Vimta Labs Limited, commented on the results, noting that "Vimta Labs delivered another strong quarter, with total income of ₹1,129 Mn, up 13.7% YoY."She attributed the robust performance to the Pharmaceutical Research and Testing Services business, which recorded healthy traction during the quarter. Ms. Vasireddi noted that while the Food Testing division has been affected by ongoing global uncertainties, the company is progressively offsetting these headwinds through improved traction in local opportunities and deeper domestic market penetration.
The Managing Director underscored the resilience of the operating model and the strength of Vimta's diversified service portfolio.
Key operational achievements reported during the quarter included:
- Completing a regulatory audit from Ukraine, affirming the company's focus on quality and compliance.
- Commencing operations in Biologics contract research and development services (CRADS), marking an important capability addition.
Looking ahead, Ms. Vasireddi stated that the company remains optimistic about industry prospects and evolving business opportunities, supported by its expanding service portfolio and customer-centric approach.
About Vimta Labs Limited
Founded in 1984 with its headquarters in Hyderabad, VIMTA LABS LTD is a leading contract research and testing organization. The company provides integrated scientific, technical, and regulatory expertise to food, agri, bio/pharmaceutical, medical device, specialty chemical, and electronics companies, supporting all stages of product development and manufacturing processes. Vimta also offers environmental assessments and testing services.VIMTALABS Stock Price Movement
Shares of Vimta Labs Limited today slipped by 5.40% to settle at ₹530.25, having shed ₹30.20 from the previous close. The equity saw significant activity in the market, with a total traded volume registering 954,406 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.